webadmin – Page 3

Walsh et al., “Fragment-to-Lead Medicinal Chemistry Publications in 2021”; J Med Chem 2023

13 January 2023/in 2023, Discovery, Publications

https://doi.org/10.1021/acs.jmedchem.2c01827

Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King’s New Year Honours

31 December 2022/in 2022, News

Cambridge, UK, 31st December 2022, Astex Pharmaceuticals, UK, congratulates Harren Jhoti, PhD, FRS, FMedSci, its co-founder, President and CEO on being honoured in the 2023 King’s New Year Honours list. Dr Jhoti has been made an Officer of the Order of the British Empire (OBE) for services to Cancer Research and Drug Discovery. Dr. Jhoti co-founded Astex […]

Martins et al., “A commentary on the use of pharmacoenhancers in the pharmaceutical industry and the implication for DMPK drug discovery strategies”; Xenobiotica 2022

20 December 2022/in 2022, Discovery, Publications

https://doi.org/10.1080/00498254.2022.2130838

Chan et al., “A multilevel generative framework with hierarchical self-contrasting for bias control and transparency in structure-based ligand design”; Nat. Mach. Intell. 2022

5 December 2022/in 2022, Discovery, Publications

https://doi.org/10.1038/s42256-022-00564-7

Jones et al., “Exploration of piperidine 3D fragment chemical space: synthesis and 3D shape analysis of fragments derived from 20 regio- and diastereoisomers of methyl substituted pipecolinates”; RSC Medicinal Chemistry, Oct 2022

25 November 2022/in 2022, Discovery, Publications

https://doi.org/10.1039/D2MD00239F

2022 EHA – Combining the IAP antagonist, tolinapant, with a DNA hypomethylating agent enhances anti-tumour mechanisms in preclinical models of T-cell lymphoma

17 November 2022/in 2022, Discovery, Posters

View Poster: Combining the IAP antagonist, tolinapant, with a DNA hypomethylating agent enhances anti-tumour mechanisms in preclinical models of T-cell lymphoma Introduction Tolinapant (ASTX660) is a potent, non-peptidomimetic antagonist of cIAP1, cIAP2 and XIAP 1, 2, and has demonstrated immunomodulatory properties in pre-clinical models of T cell lymphoma (TCL) 3. In an ongoing Phase 2 […]

Blunt et al., “Perspective on the Current State-of-the-Art of Quantum Computing for Drug Discovery Applications”; J Chem Theory Comput 2022

10 November 2022/in 2022, Discovery, Publications

https://doi.org/10.1021/acs.jctc.2c00574

Lea et al., “Cryo-EM diversifies”; Current Opinion in Structural Biology 2022

19 October 2022/in 2022, Discovery, Publications

https://doi.org/10.1016/j.sbi.2022.102469

St. Denis et al., “X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent Inhibitor”; J. Med. Chem. 2022

20 September 2022/in 2022, Discovery, Publications

https://doi.org/10.1021/acs.jmedchem.2c01044

Tamanini et al., “Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor”; ACS Med. Chem. Lett. 2022

20 September 2022/in 2022, Discovery, Publications

https://doi.org/10.1021/acsmedchemlett.2c00272

About webadmin

Entries by webadmin

Walsh et al., “Fragment-to-Lead Medicinal Chemistry Publications in 2021”; J Med Chem 2023

Astex Co-founder and CEO Harren Jhoti Awarded OBE in the King’s New Year Honours

Martins et al., “A commentary on the use of pharmacoenhancers in the pharmaceutical industry and the implication for DMPK drug discovery strategies”; Xenobiotica 2022

Chan et al., “A multilevel generative framework with hierarchical self-contrasting for bias control and transparency in structure-based ligand design”; Nat. Mach. Intell. 2022

Jones et al., “Exploration of piperidine 3D fragment chemical space: synthesis and 3D shape analysis of fragments derived from 20 regio- and diastereoisomers of methyl substituted pipecolinates”; RSC Medicinal Chemistry, Oct 2022

2022 EHA – Combining the IAP antagonist, tolinapant, with a DNA hypomethylating agent enhances anti-tumour mechanisms in preclinical models of T-cell lymphoma

Blunt et al., “Perspective on the Current State-of-the-Art of Quantum Computing for Drug Discovery Applications”; J Chem Theory Comput 2022

Lea et al., “Cryo-EM diversifies”; Current Opinion in Structural Biology 2022

St. Denis et al., “X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent Inhibitor”; J. Med. Chem. 2022

Tamanini et al., “Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor”; ACS Med. Chem. Lett. 2022

Useful links